Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Incyte Corp
(NQ:
INCY
)
64.14
+1.12 (+1.78%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Aug 23, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Incyte Corp
< Previous
1
2
...
9
10
11
12
13
14
15
16
Next >
Incyte to Present at Upcoming Investor Conference
February 15, 2022
From
Incyte
Via
Business Wire
Insiders Buy Around $112M Of 3 Stocks
February 15, 2022
US stock futures traded higher on Tuesday, amid reports that some Russian troops are returning to their bases. Investors, meanwhile, focused on some notable insider trades.
Via
Benzinga
Oncolytics Announced Updates On Clinical Trials Of New Treatment For Triple-Negative Metastatic Breast Cancer
February 10, 2022
Image provided by Pexels This post contains sponsored advertising content. This content is for informational purposes only and is not intended to be investing advice.
Via
Benzinga
Expert Ratings For Incyte
February 09, 2022
Incyte (NASDAQ:INCY) has observed the following analyst ratings within the last quarter:
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For February 9, 2022
February 09, 2022
Upgrades According to Capital One, the prior rating for Federal Realty Investment Trust (NYSE:FRT) was changed from Equal-Weight to Overweight. Federal Realty Investment...
Via
Benzinga
Why Are Incyte Shares Trading Lower Today?
February 08, 2022
Incyte Corporation's (NASDAQ: INCY)
Via
Benzinga
Recap: Incyte Q4 Earnings
February 08, 2022
Incyte (NASDAQ:INCY) reported its Q4 earnings results on Tuesday, February 8, 2022 at 07:00 AM. Here's what investors need to know about the announcement.
Via
Benzinga
The Daily Biotech Pulse: Pfizer, Amgen Shares Slip On Earnings, Editas Terminates Chief Medical Officer, Biogen Licenses Preclinical Rheumatoid Arthritis Biosimilar
February 08, 2022
Here's a roundup of top developments in the biotech space over the last 24 hours:
Via
Benzinga
Incyte Reports 2021 Fourth Quarter and Year-End Financial Results, and Provides 2022 Financial Guidance and Updates on Key Clinical Programs
February 08, 2022
From
Incyte Corporation
Via
Business Wire
Bear Market Bets In Biotech
February 07, 2022
Taken together, the SPDR S&P Biotech ETF easily broke below the long-term 200-week support for the first time since the pandemic originally hit the markets in March of 2020.
Via
Talk Markets
Incyte to Present at Upcoming Investor Conference
February 03, 2022
From
Incyte
Via
Business Wire
Eli Lilly Expects FDA Rejection For Expanded Use Baricitinib For Eczema
January 28, 2022
Based on top-line efficacy results from two pivotal Phase 3 trials Eli Lilly And Co (NYSE: LLY) has decided to
Via
Benzinga
Incyte Pulls Parsaclisib US Application For Lymphoma Treatment, Bows Out Solid Tumor Program With Merus
January 26, 2022
Incyte Corporation (NASDAQ: INCY) is
Via
Benzinga
Earnings Scheduled For February 8, 2022
February 08, 2022
Companies Reporting Before The Bell • Pfizer (NYSE:PFE) is likely to report quarterly earnings at $0.87 per share on revenue of $24.20 billion.
Via
Benzinga
The Week Ahead In Biotech (Feb. 6-12): Pfizer, AstraZeneca Earnings, Conference Presentations, IPOs And More
February 06, 2022
Biotech stocks managed to close the week ending Feb. 4 with gains. Stocks recovered along with the broader markets early in the week, but came under pressure midweek amid negative reaction to some big...
Via
Benzinga
Incyte Provides Update on Parsaclisib and MCLA-145
January 25, 2022
From
Incyte
Via
Business Wire
Promising Research in Fight Against Breast Cancer Being Amplified by an Active Biotech Sector
January 20, 2022
FN Media Group Presents USA News Group News Commentary Vancouver, BC –January 20, 2021 – USA News Group – As the 2021 San Antonio Breast Cancer Symposium (SABCS) comes to a close, many of this year’s...
Via
FinancialNewsMedia
Where Incyte Stands With Analysts
January 18, 2022
Within the last quarter, Incyte (NASDAQ:INCY) has observed the following an...
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For January 18, 2022
January 18, 2022
Upgrades Canaccord Genuity upgraded the previous rating for Fortuna Silver Mines Inc (NYSE:
Via
Benzinga
Incyte to Report Fourth Quarter and Year-End 2021 Financial Results
January 18, 2022
From
Incyte
Via
Business Wire
Breast Cancer Treatment Advancements Emerge After New Study Finds Global Deaths Increased in 2019
January 14, 2022
FN Media Group Presents USA News Group News Commentary Vancouver, BC – January 14, 2022 – USA News Group – Cancer cases are on the rise, according to a new study comparing the number of cancer...
Via
FinancialNewsMedia
Topics
Death
Exposures
Death
This Biotech Is Working With Pfizer, Merck KGaA, Roche, and Other Leaders To Develop a Better Standard of Care for Breast Cancer
January 13, 2022
Image provided by Unsplash This post contains sponsored advertising content. This content is for informational purposes only and not intended to be investing advice. Cancer is the...
Via
Benzinga
Cramer Shares His Thoughts On Incyte, Corning And More
December 22, 2021
On CNBC’s "Mad Money Lightning Round," Jim Cramer said Incyte Corporation (NASDAQ:
Via
Benzinga
4 Stocks Insiders Are Buying
December 20, 2021
When insiders purchase shares, it indicates their confidence in the company's prospects or that they view the stock as a bargain. Either way, t...
Via
Benzinga
Incyte's Topical JAK Inhibitor Under Priority FDA Review For Depigmented Skin Disorder
December 15, 2021
The FDA has accepted for review Incyte Corporation's (NASDAQ: INCY) supplemental marketing application seeking approval for ruxolitinib cream 1.5% (Opzelura), a...
Via
Benzinga
Incyte Announces Acceptance and Priority Review of sNDA for Ruxolitinib Cream (Opzelura™) as a Treatment for Patients with Vitiligo
December 14, 2021
From
Incyte
Via
Business Wire
Incyte to Present at Upcoming Investor Conferences
December 14, 2021
From
Incyte
Via
Business Wire
Why Are Datadog, Zscaler, Airbnb, Fortinet, Lucid Trading Higher Premarket?
December 13, 2021
Airbnb, Inc (NASDAQ: ABNB), Fortinet, Inc (NASDAQ: FTNT), Palo Alto Networks, Inc (NASDAQ: PANW), Lucid Group, Inc (NASDAQ: LCID), Zscaler, Inc (NASDAQ: ZS), and Datadog, Inc (...
Via
Benzinga
MorphoSys and Incyte Announce Additional Real-World Evidence Results from RE-MIND2 Study of Tafasitamab (Monjuvi®) in Combination with Lenalidomide for the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma
December 11, 2021
From
Incyte
Via
Business Wire
Annual Changes To The Nasdaq-100 Index
December 11, 2021
The reconstituted Nasdaq index for 2022 (effective Dec. 20, 2021) has six new members; they replace FOX, TCOM, INCY, CDW, CERN, and CHKP.
Via
Talk Markets
< Previous
1
2
...
9
10
11
12
13
14
15
16
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.